Waters Seen Benefiting From BD Turnaround, Pharma Manufacturing Tailwinds, RBC Says

MT Newswires Live07-09 20:23

Waters (WAT) could unlock stronger growth by turning around the recent acquired Becton Dickinson (BDX) biosciences and diagnostics businesses while benefiting from resilient demand tied to drug manufacturing, RBC Capital said in a Thursday note.

Analysts said the acquired assets were under-managed rather than structurally weak and sees Waters' management applying its turnaround expertise to revive growth.

RBC also expects the company to benefit from industry consolidation opportunities and its roughly 15% exposure to pharmaceutical manufacturing, which could gain from US re-shoring trends.

RBC initiated coverage with an outperform rating and a $435 price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment